| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192339 | European Journal of Surgical Oncology (EJSO) | 2011 | 7 Pages |
Abstract
The combined modality of TACE and 3-DCRT is a promising treatment for unresectable HCC. A large-scale, prospective randomized trial should be performed to confirm the utility of this combined therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L.-T. Xu, Z.-H. Zhou, J.-H. Lin, Z. Chen, K. Wang, P. Wang, X.-Y. Zhu, Y.-H. Shen, Z.-Q. Meng, L.-M. Liu,